Geode Capital Management LLC Raises Holdings in Keros Therapeutics, Inc. (NASDAQ:KROS)

Geode Capital Management LLC lifted its holdings in Keros Therapeutics, Inc. (NASDAQ:KROS) by 5.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 765,436 shares of the company’s stock after purchasing an additional 39,815 shares during the quarter. Geode Capital Management LLC owned 1.89% of Keros Therapeutics worth $12,120,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Clearbridge Investments LLC bought a new position in Keros Therapeutics during the 4th quarter valued at about $3,009,000. Norges Bank bought a new position in Keros Therapeutics during the fourth quarter valued at approximately $1,027,000. NEOS Investment Management LLC boosted its holdings in Keros Therapeutics by 28.4% in the fourth quarter. NEOS Investment Management LLC now owns 35,663 shares of the company’s stock worth $565,000 after purchasing an additional 7,885 shares during the last quarter. JPMorgan Chase & Co. grew its position in Keros Therapeutics by 585.9% in the 4th quarter. JPMorgan Chase & Co. now owns 213,431 shares of the company’s stock worth $3,379,000 after purchasing an additional 182,314 shares during the period. Finally, EntryPoint Capital LLC bought a new position in shares of Keros Therapeutics during the 4th quarter valued at $183,000. 71.56% of the stock is owned by institutional investors.

Keros Therapeutics Price Performance

Keros Therapeutics stock opened at $14.30 on Tuesday. The firm’s 50 day moving average price is $11.25 and its 200-day moving average price is $28.70. Keros Therapeutics, Inc. has a 1 year low of $9.12 and a 1 year high of $72.37. The stock has a market cap of $580.04 million, a P/E ratio of -2.74 and a beta of 1.39.

Keros Therapeutics (NASDAQ:KROS) last announced its quarterly earnings results on Wednesday, February 26th. The company reported ($1.14) EPS for the quarter, topping the consensus estimate of ($1.36) by $0.22. The business had revenue of $3.04 million for the quarter, compared to analysts’ expectations of $37.32 million. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. As a group, equities analysts expect that Keros Therapeutics, Inc. will post -4.74 EPS for the current year.

Insider Buying and Selling at Keros Therapeutics

In other Keros Therapeutics news, major shareholder Adar1 Capital Management, Llc acquired 934,258 shares of the company’s stock in a transaction on Wednesday, April 9th. The stock was acquired at an average cost of $10.13 per share, with a total value of $9,464,033.54. Following the purchase, the insider now directly owns 4,392,737 shares of the company’s stock, valued at approximately $44,498,425.81. This represents a 27.01 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. 22.90% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several brokerages recently commented on KROS. Piper Sandler cut their price objective on Keros Therapeutics from $40.00 to $15.00 and set an “overweight” rating for the company in a report on Friday, January 17th. Guggenheim reissued a “neutral” rating on shares of Keros Therapeutics in a report on Friday, January 17th. Truist Financial reduced their target price on shares of Keros Therapeutics from $43.00 to $25.00 and set a “buy” rating for the company in a report on Wednesday, April 9th. Wells Fargo & Company cut their price objective on shares of Keros Therapeutics from $28.00 to $26.00 and set an “overweight” rating for the company in a research report on Thursday, February 27th. Finally, Cantor Fitzgerald downgraded Keros Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Tuesday, January 21st. Six investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $40.33.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.